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ABSTRACT
Endocrine therapy has successfully been used to
treat estrogen receptor (ER)-positive breast cancer,
but this invariably fails with cancers becoming refrac-
tory to treatment. Emerging evidence has suggested
that fluctuations in ER co-regulatory protein expres-
sion may facilitate resistance to therapy and be in-
volved in breast cancer progression. To date, a small
number of enzymes that control methylation status
of histones have been identified as co-regulators
of ER signalling. We have identified the histone H3
lysine 9 mono- and di-methyl demethylase enzyme
KDM3A as a positive regulator of ER activity. Here,
we demonstrate that depletion of KDM3A by RNAi
abrogates the recruitment of the ER to cis-regulatory
elements within target gene promoters, thereby in-
hibiting estrogen-induced gene expression changes.
Global gene expression analysis of KDM3A-depleted
cells identified gene clusters associated with cell
growth. Consistent with this, we show that knock-
down of KDM3A reduces ER-positive cell prolifer-
ation and demonstrate that KDM3A is required for
growth in a model of endocrine therapy-resistant dis-
ease. Crucially, we show that KDM3A catalytic ac-
tivity is required for both ER-target gene expression
and cell growth, demonstrating that developing com-
pounds which target demethylase enzymatic activity
may be efficacious in treating both ER-positive and
endocrine therapy-resistant disease.
INTRODUCTION
Approximately two-thirds of newly diagnosed breast can-
cers (BCa) express estrogen receptor- (ER, hereafter
called ER) and require ER-mediated transcriptional activa-
tion for tumour growth. Therapy for ER-positive BCa has
focussed on abrogating ER activity by preventing binding
of the ER to its activating hormone estrogen (1). Unfortu-
nately, cancers become resistant to such endocrine therapies
and progress due to poorly defined molecular events that
enable ER function in the absence of ligand (2). Evidence
suggests that fluctuations in the activity of ER co-regulatory
proteins play a role in BCa progression and could facilitate
resistance to therapy (3–7). Developing therapies which tar-
get ER co-regulatorsmay therefore provide effectiveways of
treating ER-positive BCa.
Histone lysine methylation is an important regulator
of transcription and aberrant methylation patterns have
been associated with oncogenesis (8,9). Mono-/di-/tri-
methylation (me1/2/3) of specific lysines in histones H3
and H4 play an important role in regulating gene expres-
sion by altering chromatin structure to activate or repress
transcription (10,11). Histone methyltransferases (HMTs)
are a family of SET domain-containing enzymes that catal-
yse the addition of methyl groups to distinct lysine residues
on histones H3 and H4. Removal of histone methyla-
tion is catalysed by histone demethylase (HDM) enzymes
(12,13). There are eight characterized HDM enzyme fam-
ilies (termed KDMs) all of which, with the exclusion of
KDM1, contain a Jumanji-C (JmjC) demethylase domain
(14). Both HMT enzymes and HDM enzymes have been di-
rectly associated with ER regulation and BCa development.
For example, the HMT EZH1 is overexpressed in BCa, the
HDM KDM4C promotes BCa cell growth and metasta-
sis, and the HDMs KDM1 and KDM4B are both required
for ER-mediated transcription (15–21). KDM4B is also re-
quired for BCa cell growth and expression of the ER and
ER pioneer proteins (19,20,22). These findings suggest a
role for dysregulated histone methylation in BCa develop-
ment and identify HMTs andHDMs as potential therapeu-
tic targets.
Using an siRNA screen we identified that the HDM
KDM3A was required for ER target gene expression.
KDM3A is a member of the 2-oxyglutarate/Fe(II)-
dependent JmjC family of HDMs that demethylate tran-
scriptionally repressive H3K9 mono- and di-methyl marks
(23,24). KDM3A is up-regulated by HIF-1 during hy-
poxia and KDM3A expression is elevated in both bladder
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and lung cancer (25–27). Depletion of KDM3A has been
shown to reduce bladder, lung, colon and hepatocellular
carcinoma cell growth (25,27,28). KDM3A also regulates
androgen receptor (AR) activity in prostate cancer cell lines
(23).
Here, we show thatKDM3Adepletion reduces ER-target
gene expression and abrogates the recruitment of the ER to
cis-regulatory elements within target gene promoters. Mi-
croarray analysis determined that genes down-regulated by
KDM3A depletion play crucial roles in cell growth and
this was supported by proliferation assays in BCa cell lines.
Importantly, the catalytic activity of KDM3A is crucial
for both ER-target gene expression and cell proliferation
in breast cancer. Furthermore, we have demonstrated that
KDM3A knockdown inhibits ER-target gene expression
and cell proliferation in a model of endocrine therapy-
resistant BCa. Together, our findings identify that KDM3A
is essential for ER signalling and confirm KDM3A as an
important BCa therapeutic target.
MATERIALS AND METHODS
Cell culture
MCF-7, T47D, BT-474, ZR751 and HEK293 cells
were maintained in RPMI-1640 media (Sigma) con-
taining 10% foetal-calf serum (FCS) (Gibco) and 1%
penicillin/streptomycin (Sigma). For estrogen stimulation
assays, cells were grown in phenol red-free RPMI-
1640 media (Gibco) supplemented with 10% serum
stripped FCS (Hyclone) and 1% penicillin/streptomycin
for 24 (KDM3A knockdown chromatin immunopre-
cipitation (ChIP) experiments) or 48 h (ChIP/gene
expression/microarray experiments) prior to the addition
of 10 nM 17--estradiol (E2) (Sigma) for 45 min (ChIP)
or 4 h (gene expression/microarray analysis). MMU2
cells were maintained in phenol red-free RPMI-1640
media supplemented with 10% dialysed serum (Gibco)
and 1% penicillin/streptomycin. MCF-10A cells were
maintained in DMEM-F12 (Sigma) media containing 5%
horse serum (Sigma), 10 g/ml insulin (Sigma), 0.5 g/ml
EGF (Sigma), 100 ng/ml cholera toxin (Sigma) and 1%
penicillin/streptomycin.
siRNA transfection
The initial siRNA library screen was conducted as
described in (19). Two KDM3A targeting siRNAs
(siKDM3A-B and siKDM3A-C), an ER targeting siRNA
(siER) and a non-silencing scrambled control siRNA
(siSCR) were utilized in this study. All siRNAs were
purchased from Sigma and sequences are shown in Sup-
plementary Table S2. Cell lines were transfected with
individual siRNAs using Lipofectamine RNAiMAX
(Invitrogen) to a final concentration of 25 nM according
to manufacturer’s instructions and as previously described
(29). To assess KDM3A and ER expression and global
H3K9me1/2 status, protein from transfected cells was har-
vested in SDS-sample buffer and subject to polyacrylamide
gel electrophoresis (SDS-PAGE) prior to immunoblotting
with specific antibodies as described in (30) (antibody
details: Supplementary Table S3). For gene expression
analysis, RNA was extracted using TRIzol (Ambion, Life
Technologies) and cDNA was generated to be analysed by
quantitative PCR (qPCR) as previously described (29) (for
primer sequences see Supplementary Table S4).
Microarray analysis
Transfections were set up and RNA extraction performed
as described above. Gene expression data were obtained by
hybridizing triplicate samples to Illumina HT-12 version 4
BeadChips, although one sample failed due to low amount
of cRNA (siKDM3A + E2). Raw data for the remaining
11 samples were processed and analysed using R statisti-
cal software (http://www.R-project.org) and BioConductor
(31) packages as described below. Background corrected
signal intensities were variance-stabilized and normalized
using the ‘vsn’ package (32). Quality control plots did not
reveal any further outlier samples. The dataset was then fil-
tered to remove probes not detected (detection score<0.95)
in any of the samples, resulting in a final dataset of 28 909
probes.
Statistical analysis was performed using the LinearMod-
els forMicroarray Analysis (limma) package (33). Compar-
isons to find genes changing in response to estrogen stimula-
tion in the control and knockdown groups, as well as differ-
ences between the control and knockdown groups, were per-
formed. Multiple testing correction was applied using the
false discovery rate controlling procedure of Benjamini and
Hochberg (34). Probes with adjusted P-values <0.05 were
considered significantly differentially expressed and results
were annotated with the annotation package illuminaHu-
manv4 (DunningM, Lynch A and EldridgeM. illuminaHu-
manv4.db: Illumina HumanHT12v4 annotation data (chip il-
luminaHumanv4). R package version 1.22.1).
Gene ontology analysis
Gene lists were analysed using the Functional Annotation
tool of the DAVID Bioinformatics Resource v6.7 (35,36)
and against a background of the Illumina HumanHT-12
gene list. Analysis was performed using default settings
and the SP PIR KEYWORDS, GOTERM BP FAT (Bio-
logical Processes), GOTERM MF FAT (Molecular Func-
tions) and KEGG PATHWAY databases. The top 20 en-
riched gene ontology (GO) terms ranked by their Fisher
Exact P-values are shown in Supplementary Table S1. Fold
enrichment indicates the number genes found in the gene
list for each GO term compared to the number you would
expect by random chance from a gene list of the size anal-
ysed.
Chromatin immunoprecipitation
Chromatin was harvested fromMCF-7 and T47D cells and
fractionated by sonication as described (19). ChIP was per-
formed using the Auto ChIP protein A kit (Diagenode) in
the SX-8G IP-Star Compact Automated System (Diagen-
ode) following manufacturer’s instructions. Briefly, 30g of
DNA and 2 g of ER antibody, 3 g of KDM3A antibody,
1 g of H3K9me1/2 antibodies and equal amounts of iso-
type control antibodies were used for each ChIP reaction
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which comprised of 2-h antibody coating and 10-h immuno-
precipitation incubation periods (antibody details: Supple-
mentary Table S2). Following ChIP, eluted DNA and input
samples taken from the original sonicated sample were sub-
ject to cross-link reversal and qPCR using primers specific
to pS2 and GREB1 promoter elements and CCND1, MYC
andXBP1 distal enhancer elements (primer sequences: Sup-
plementary Table S4). Data were calculated as % input (as
described in (19)). Data were presented as the average fold
difference of % input between different experimental arms
(detailed in figure legends) of at least three independent ex-
periments.
RNAi rescue
RNAi rescue experiments were performed using pLenti-
V5-KDM3A and the demethylase-inactive pLenti-V5-
KDM3AH1120G/D1122N plasmids. The pLenti constructs
were generated by cloning the previously described pCMV-
HA-KDM3A and pCMV-HA-KDM3AH1120G/D1122N
(26) plasmids into the pLenti6 backbone upstream and
in-frame with the V5-tag via the pENTR shuttling vector
using the pENTR/D-TOPO kit (Invitrogen) following
manufacturer’s instructions. Two silent (codon switch)
mutations were introduced into the siKDM3A-B tar-
get sequence within both pLenti6-V5-KDM3A and
pLenti6-V5-KDM3AH1120G/D1122N plasmids by site di-
rected mutagenesis using the Quickchange II kit (Agilent)
incorporating the following primer sequences; F: 5′-
GGGAATAAAGGCAAACTGCCCCTGCTCAAACA
GGCAATTCAAAC-3′ and R: 5′-GTTTGAATTGCCTG
TTTGAGCAGGGGCAGTTTGCCTTTATTCCC-3′ to
allow ectopic expression of KDM3A in cells depleted of
endogenous KDM3A.
To assess demethylase activities of KDM3A and
KDM3AH1120G/D1122N, both plasmids were transfected
into HEK293T cells and subject to immunofluorescence
using H3K9me1/me2 methylation state-specific antibodies.
Briefly, HEK293 cells plated onto sterile 22 mm × 22 mm
coverslips and transfected for 48 h with 0.5 g pLenti6-V5-
KDM3A plasmids using TransIT-LT1 reagent (Mirus Bio)
were fixed in 4% paraformaldehyde for 20 min at room tem-
perature prior to consecutive incubations in 0.1% Triton
(Sigma) for 10 min and 4% goat serum (DAKO) for 30 min
at room temperature. Mixtures containing V5 and either
H3K9me1/2/3-specific antibodies or isotype controls
diluted in 4% goat serum to a final concentration of 1:1000
and 1:500, respectively (antibody details: Supplementary
Table S3), were added to cells and incubated overnight
at 4◦C. A secondary antibody only control sample was
also prepared by adding 4% goat serum to cells prior to
overnight incubation. The next day, coverslips were washed
in phosphate buffered saline (PBS) and secondary antibody
mixes (prepared to a final dilution of 1:500 in 4% goat
serum) were added for 1 at room temperature (antibody
details: Supplementary Table S3) prior to washing in PBS
and addition of Vectorshield DAPI mounting media (Vec-
tor Laboratories). Coverslips were mounted on microscope
slides and analysed using a Leica DMRmicroscope system
(Leica Microsystems). Once it was confirmed that neither
the isotype control or secondary antibody stained cells
showed any immunofluorescence, representative images of
DAPI stained cells showing ectopic expression of KDM3A
proteins (as indicated by V5 staining) and H3K9me1/me2
methylation were captured using SPOT Advanced software
(Spot Imaging).
In preparation for RNAi rescue experiments, the
pLenti6-V5-KDM3A plasmids were individually packaged
into lentivirus in HEK293T cells using the ViraPower
Lentiviral Packaging Mix (Invitrogen) following manufac-
turer’s instructions. Virus was concentrated by ultracen-
trifugation at 26 500 x g for 2 h at 4◦C and re-suspended
in 1 ml of RPMI-1640 media ready for transduction into
KDM3A-depleted MCF-7 cells. Briefly, MCF-7 cells
were plated onto 12-well microtitre plates (Corning) and
transfected with 25 nM siKDM3A-B for 2 h prior to the
addition of KDM3A or KDM3AH1120G/D1122N lentivirus.
Parallel experiments were also performed in which MCF-7
cells were transfected with siSCR or siKDM3A-B but not
transduced with lentivirus so that knockdown efficiency
and relative ER-target gene expression could be assessed.
Cells were grown for 65 h prior to RNA and protein extrac-
tion using TRIzol following manufacturer’s instructions.
cDNA was generated from extracted RNA and analysed
by qPCR for KDM3A and ER-target gene expression
(primer sequences: Supplementary Table S4). Gene ex-
pression data from each experiment was expressed relative
to the expression measured in siSCR non-transduced
MCF-7 cells and data were combined from at least three
independent experiments. Protein extracted from RNAi
rescue experiments was assessed by western blot analysis to
confirm equal ectopic KDM3A expression.
Cell growth analysis
Cell growth was assessed in siRNA-transfected MCF-7,
T47D and MMU2 cells using cell counts, a BrdU ELISA
assay (Roche) and the Incucyte Zoom live cell imager
(Essen Bioscience). In each case MCF-7 and T47D cells
were grown in phenol red-free RPMI-1640 media supple-
mented with 10% serum stripped FCS, 10 nM E2 and 1%
penicillin/streptomycin.
For cell counts, siRNA-transfected MCF-7 and T47D
cells were grown for 96 h on six-well plates prior to man-
ual counting using a haemocytometer, MMU2 cells were
grown for 72 h. Data were presented as the average fold
difference in cell number relative to siSCR-transfected cells
from three independent experiments. For phenotypic rescue
analysis, RNAi rescue experiments were performed as pre-
viously described except cells were incubated for 156 h prior
to cell counting. Data were presented as the mean cell num-
ber from three independent experiments.
The BrdU ELISA assay was performed following man-
ufacturer’s instructions (Roche). Briefly, cells were trans-
fectedwith siRNAand grown for 72 h in 96-well plates prior
to the addition of BrdU labelling solution. Cells were incu-
bated for 16 h to allow BrdU incorporation and then the
cells were washed, fixed and stained using a BrdU antibody
conjugate. Cells were incubated for 90 min prior to stain-
ing using the BrdU substrate solution for 10 min before the
reaction was stopped by the addition of 1 M H2SO4. The
absorbance at 450 nm of each well was measured using the
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Bio-Rad 680 ELISA reader as an indication of BrdU incor-
poration. Data were calculated for each experimental arm
as the mean absorbance from a minimum of five wells and
was presented as the mean fold difference in absorbance rel-
ative to siSCR transfected cells from 3 independent experi-
ments.
The Incucyte Zoom live cell imager was used to as-
sess relative cell confluence between siRNA transfected
MCF-7, T47D, MMU2 and MCF-10A cells. MMU2 cells
and MCF-10A cells were grown in their respective nor-
mal growth media. Briefly, cells were transfected in 12-well
plates and images from nine fields per well were taken every
6 h over 54 h (MCF-10A and MCF-7) 60 (MMU2) and 84
h (T47D) by the Incucyte Zoom live cell imager. The dif-
ference in incubation times between cell lines was depen-
dent on differing cell growth rates of siSCR transfected cells.
The Incucyte Zoom software package was trained to iden-
tify cells from each cell line and measure the % confluence
of each well. Cell confluence was normalized for each well
at the 0 time point and the relative change in cell confluence
(hence growth) was calculated for each time point there-
after. Data were presented as the mean relative cell conflu-
ence at each time point from at least three independent ex-
periments.
Cell cycle analysis
Transfected MCF-7 and T47D cells were grown for 96
h in phenol red-free RPMI-1640 media supplemented
with 10% serum-stripped FCS, 10 nM E2 and 1%
penicillin/streptomycin prior to growth media being col-
lected and cells being trypsinized. Growth media and
trypsinized cells were combined, pelleted and washed in
PBS before re-suspension in 100 l citrate buffer (0.25 M
Sucrose, 40 mM sodium citrate, pH 7.6). DNA staining
and lysis buffer (20 g/ml propidium iodide (Sigma), 0.5%
NP-40 (Calbiochem), 250g/mlRNaseA (Qiagen) 0.5mM
ethylenediaminetetraacetic acid (EDTA), in PBS) was pre-
pared and 400 l added to the cell suspension prior to incu-
bation overnight in the dark at 4◦C. Following incubation,
10 000 propidium iodide-stained cells were measured using
the FACScan (Becton Dickenson) together with CellQuest
software (Beckton Dickenson) and analysed using Cyflogic
software (CyFlo Ltd). The percentage of cells in each cell
cycle phase was determined and data presented as the mean
percentage of cells from three independent experiments.
RESULTS
KDM3A is required for ER signalling
To identify HMT and HDM enzymes required for ER-
mediated transcriptional regulation, an unbiased siRNA
library screen was performed in which each of the hu-
man HMT and HDM enzymes were individually depleted
in MCF-7 cells using a pool of three siRNAs. Receptor
activity was assessed by measuring pS2 gene expression
(19). The screen identified that the HDM KDM3A was
required for pS2 expression (Supplementary Figure S1).
Two individual siRNAs (siKDM3A-B and siKDM3A-C)
were shown to robustly down-regulate protein expression of
Figure 1. KDM3A is required for ER signalling. (A) MCF-7 and T47D
cells were transiently transfected with a control siRNA (siSCR) or two in-
dependent KDM3A targeting siRNAs (siKDM3A-B and siKDM3A-C)
and grown for 72 h prior to western analysis using antibodies specific to
KDM3A and -tubulin. -Tubulin expression was used to confirm equal
amounts of total protein between samples. (B) MCF-7 and T47D cell lines
were subject to transient transfection with either siSCR or siKDM3A-B
siRNAs and grown in steroid-depleted medium for 48 h prior to 4 h treat-
ment with vehicle or 10 nM E2 and subsequent RNA extraction. Resul-
tant cDNA was analysed for pS2 and GREB1 expression by qPCR. Data
are the average of three independent experiments ± SEM. Gene expres-
sion is shown relative to that measured in vehicle treated siSCR trans-
fected cells. P-values were determined by Student’s t-test (* denotes P <
0.05). (C) MCF-7 cells were treated as in (B) prior to RNA extraction
and hybridization to an Illumina HT12.2 Bead CHIP array. The num-
ber of ER-regulated genes (defined as genes significantly (P < 0.05) up-
or down-regulated 1.5-fold by E2 stimulation in siSCR transfected cells
(n = 534)), and the number of KDM3A-regulated genes (defined as genes
significantly up- or down-regulated 1.5-fold byKDM3A knockdown com-
pared to siSCR controls in E2 stimulated conditions (n = 3426)), was de-
termined. E2-stimulated genes down-regulated byKDM3Aknockdown or
E2-repressed genes up-regulated byKDM3Aknockdownwere classified as
E2-KDM3A-regulated genes (n = 222).
KDM3A compared to a scrambled control (siSCR) (Fig-
ure 1A) and both down-regulated expression of the ER-
target genes pS2 and CCND1 in MCF-7, T47D, ZR751
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and BT474 cells (Supplementary Figure S2A). KDM3Ade-
pletion using siKDM3A-B was also shown to significantly
down-regulate the ER-target genes pS2 and GREB1 in the
presence and absence of 10 nM-estradiol (E2) (Figure 1B).
Importantly, KDM3A knockdown did not affect ER pro-
tein expression, indicating that the observed effect on ER-
target gene expression was not due to down-regulation of
the receptor (Supplementary Figure S2B).
To interrogate the full extent of KDM3A regulation
on ER signalling, we assessed basal and E2-stimulated
global gene expression changes inKDM3A-depletedMCF-
7 cells by microarray analysis. Briefly, cells were trans-
fected in steroid-depleted conditions with either siSCR or
siKDM3A-B for 48 h prior to treatment with vehicle or 10
nM E2 for 4 h before RNA extraction and hybridization to
an Illumina HT12.2 Bead CHIP array. Successful KDM3A
depletion was confirmed by qPCR (Supplementary Figure
S2C).
Genes significantly up- or down-regulated 1.5-fold be-
tween vehicle and E2-treated siSCR transfected cells were
deemed to be estrogen regulated (E2-regulated genes).
We identified that 42% of E2-stimulated or repressed
genes were respectively down- or up-regulated at least
1.5-fold in KDM3A-depleted cells compared to siSCR
controls (termed E2-KDM3A regulated genes), indicating
that KDM3A regulates a significant proportion of the
ER transcriptome (Figure 1C). The expression of a large
number of non ER-regulated genes was also affected by
KDM3A knockdown, indicating that KDM3A also in-
fluences E2-independent transcription. A number of E2-
stimulated genes down-regulated by KDM3A depletion are
reported to play important roles in BCa progression. For
example, PIM1 is an ER regulated proto-oncogene that has
been shown to play a role in BCa cell proliferation, migra-
tion and metastasis and is associated with high grade tu-
mours (37,38); KRT13 has been associated with BCa cell
growth and metastasis (39) and LOXL4 is an established
promoter of cell invasion (40–42) (Supplementary Figure
S2D). It should be noted that any E2-KDM3A regulated
genes which are up- or down-regulated 1.5-fold post 4 h E2
treatment would not be identified in this analysis but may
still play a role in BCa progression.
KDM3A is required for ER recruitment to ER-responsive el-
ements
We next sought to determine the mechanism by which
KDM3A regulates ER signalling. KDM3A is a JmjC
domain-containing HDM enzyme that removes tran-
scriptionally repressive H3K9 mono- and di-methyl
(H3K9me1/2) marks allowing DNA to be more accessible
to transcription factors and the RNA polymerase machin-
ery (10,11,23). We observed increased global H3K9me2
levels by western analysis in KDM3A-depletedMCF-7 and
T47D cells confirming that the HDM activity of KDM3A
is functional in ER-positive BCa cell lines (Figure 2A). We
therefore hypothesized that KDM3A facilitates receptor
activity by demethylating H3K9me1/2 at specific ER-target
gene cis-regulatory elements.
To confirm E2-stimulated ER recruitment and
H3K9me1/2 demethylation at ER-target gene cis-
Figure 2. KDM3A regulates H3K9me1/2 demethylation and ER recruit-
ment to target genes. (A) MCF-7 and T47D cells were transiently trans-
fected with siSCR, siKDM3A-B or siKDM3A-C and grown for 48 h prior
to western analysis using antibodies specific to H3K9me2 and histone H3.
Histone H3 expression was used to confirm equal amounts of total histone
protein between samples. (B–E) MCF-7 cells were transiently transfected
with either siSCR or siKDM3A-B and grown for 24 h prior to treatment
with vehicle or 10 nM E2 for 45 min followed by ChIP analysis using an-
tibodies specific to KDM3A (B), H3K9me2 (C), H3K9me1 (D), ER (E)
and isotype controls (IgG). Recruitment to ERE2within the pS2 promoter
and an ERE within theGREB1 promoter was assessed by qPCR. Data are
an average of at least 3 independent experiments ± SEM and is expressed
relative to the level of recruitment measured in vehicle treated siSCR trans-
fected cells.P-valueswere determined byTurkey’smultiple comparison test
(* denotes P < 0.05).
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regulatory elements, we performed ChIP in MCF-7
cells treated with or without 10 nM E2 for 45 min. Using
anti-ER, anti-H3K9me1 and anti-H3K9me2 antibodies
and isotype controls, we confirmed that E2 stimulates
ER recruitment and H3K9me1/2 demethylation at two
estrogen response elements (EREs) within the promoter of
pS2 (ERE1 and ERE2) and one ERE within the promoter
of GREB1 (Supplementary Figure S3A–C). ChIP using
an anti-KDM3A antibody indicated that KDM3A was
present at EREs in E2-deprived conditions but was removed
from chromatin following ligand stimulation (Supplemen-
tary Figure S3D). The presence of KDM3A at EREs under
E2-deprived conditions correlates with the observation
that KDM3A depletion reduces basal transcription of
ER-regulated genes (Figure 1B; Supplementary Figure
S2D).
To further define the role of KDM3A at ER-target gene
promoters, H3K9 methylation and ER recruitment was
assessed by ChIP in MCF-7 cells depleted of KDM3A.
Knockdown of the enzyme by siKDM3A-B was con-
firmed at pS2 and GREB1 EREs under E2-deprived condi-
tions (Figure 2B; Supplementary Figure S4A). Importantly,
KDM3A depletion elevated the basal level of H3K9me2 at
both pS2 and GREB1 EREs and abrogated H3K9me1/2
demethylation following hormone stimulation at pS2EREs,
demonstrating that KDM3A is required to remove tran-
scriptionally repressive marks at these loci (Figure 2C and
D; Supplementary Figure S4B and C). In contrast, H3K9
demethylation remained evident upon E2 stimulation at the
GREB1ERE despite KDM3A knockdown, suggesting that
otherHDMswhich demethylateH3K9may compensate for
KDM3A depletion at this locus.
Importantly, reduced KDM3A levels attenuated ER re-
cruitment to both pS2 and GREB1 cis-regulatory elements
in basal and estrogen-stimulated conditions (Figure 2E;
Supplementary Figure S4D). The inhibition of ER recruit-
ment upon E2 stimulation was more pronounced at pS2
EREs than the GREB1 ERE which correlates with the
comparative effects of KDM3A depletion on H3K9me1/2
status at these sites. Inhibition of ER recruitment to cis-
regulatory elements upon KDM3A depletion was also ob-
served in T47D cells (Supplementary Figure S4E). To-
gether, the data demonstrates that KDM3A regulates ER-
mediated transcription by facilitating binding of the recep-
tor to EREs via demethylation of H3K9me2/1.
Considering many ER–chromatin interactions occur in
non-promoter regions we also investigated the effect of
KDM3A knockdown on ER recruitment at distal enhancer
elements.We observed thatKDM3Aknockdown abrogated
ER recruitment to enhancer elements of the ER target genes
CCND1, MYC and XBP1, demonstrating that the regula-
tory role of KDM3A on ER recruitment is not confined to
target gene promoters and supporting the hypothesis that
KDM3A is required for ER signalling (Supplementary Fig-
ure S5A–C).
KDM3A catalytic activity is required for ER target gene ex-
pression
Compounds which target the catalytic activity of JmjC
domain-containing KDM family members are being devel-
oped as potential cancer therapeutics (43,44). The validity
of KDM3A as a potential therapeutic target in ER-positive
BCa therefore relies on the catalytic activity of the enzyme
driving ER signalling. The observation that KDM3A de-
pletion concurrently abrogates H3K9me1/2 demethylation
and ER recruitment suggests that KDM3A catalytic ac-
tivity is required for successful ER signalling. To confirm
this hypothesis, we assessed ER-target gene expression us-
ing RNAi-rescue experiments in MCF-7 cells depleted of
endogenous KDM3A, but overexpressing siRNA-resistant
wild-type or demethylase-inactive (KDM3AH1120G/D1122N
(26)) variants of the enzyme.
Firstly, the respective catalytic activity of the KDM3A
variants was confirmed by immuno-fluorescence us-
ing H3K9 methylation state-specific antibodies in
HEK293 cells over-expressing either KDM3A or
KDM3AH1120G/D1122N. Ectopically-expressed wild-type,
but not the demethylase-inactive variant, was found to
reduce global H3K9me1/2 (Figure 3A), while H3K9me3,
which is not a demethylation target of KDM3A, remained
unchanged (Supplementary Figure S6A). We next in-
troduced KDM3A or KDM3AH1120G/D1122N variants
into siKDM3A-B-transfected MCF-7 cells via lentiviral
transduction and measured KDM3A, pS2, GREB1 and
CCND1 gene expression by qPCR. KDM3A mRNA
levels were approximately 23-fold higher in KDM3A and
KDM3AH1120G/D1122N transduced cells than control siSCR
transfected cells, demonstrating equal over-expression of
KDM3A by both plasmids (Figure 3B). Equal KDM3A
and KDM3AH1120G/D1122N protein expression was also
confirmed by western blot analysis (Supplementary Figure
S6C). Importantly, expression of pS2, GREB1 and CCND1
was significantly elevated in KDM3A-transduced cells
compared to cells transduced with KDM3AH1120G/D1122N
(Figure 3C–E). Expression of GREB1 and CCND1 demon-
strated almost complete rescue in KDM3A-transduced
cells to levels equivalent to the siSCR control, whereas
KDM3AH1120G/D1122N demonstrated no appreciable up-
regulation of ER-target gene expression. This confirms that
KDM3A catalytic activity is required for ER-regulated
gene expression, and suggests that compounds targeting
KDM3A catalytic activity may be effective in abrogating
ER signalling.
KDM3A is required for BCa cell growth
ForKDM3A to be an effective therapeutic target, depletion
of KDM3A must affect cancer cell growth and/or cell sur-
vival. To this end, we performed functional GO analysis on
all KDM3A-regulated genes identified by ourmicroarray to
reveal which cellular processes are affected by KDM3A de-
pletion. We identified a significant number of genes down-
regulated by KDM3A knockdown that are required for cell
cycle regulation and DNA replication (Supplementary Ta-
ble S1). Validation of a subset of genes by qPCR in MCF-7
and T47D cells confirmed that KDM3A depletion down-
regulates a number of cell cycle regulatory genes associ-
ated with both G1/S transition (CCND1, CCNA2, CDK2,
CDK4) and G2/M transition (CDK1, CDC25A), suggest-
ing that KDM3A is a positive regulator of BCa cell growth
(Figure 4A; Supplementary Figure S7A).
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Figure 3. KDM3A catalytic activity is required for ER signalling. (A) HEK293 cells were transiently transfected with 0.5 g of either V5-tagged wild-
type KDM3A or demethylase-inactive KDM3AH1120G/D1122N–expressing plasmids and grown for 48 h prior to immunofluorescence using V5 (green),
H3K9me1 and H3K9me2 (red) specific antibodies. Ectopic expression of wild type KDM3A (left panel) and KDM3AH1120G/D1122N (right panel) was
detected by V5 staining. Cells were counterstained using DAPI. The broken circles in DAPI and H3K9me1/2 fluorescent cell images indicate the position
of cells ectopically expressing KDM3A. (B–E) MCF-7 cells were transiently transfected with siKDM3A-B and incubated for 2 h prior to transduction
with lentivirus expressing either wild-type KDM3A or KDM3AH1120G/D1122N. Parallel control experiments were also performed in which MCF-7 cells
were transfected with siSCR or siKDM3A-B. Cells were grown for 65 h prior to RNA extraction and resultant cDNA was analysed for KDM3A (B), pS2
(C), GREB1 (D) and CCND1 (E) expression by qPCR. Data shown is for all siKDM3A transfected cells and is the average of at least three independent
experiments ± SEM. Gene expression is shown relative to expression measured in siSCR control cells. P-values were determined by Turkey’s multiple
comparison test (* denotes P < 0.05).
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Figure 4. KDM3A is required for ER positive BCa cell growth. (A) Gene expression analysis of cell cycle regulatory genes (CCND1, CCNA2, CDK2,
CDK4, CDK1 and CDC25A) between siSCR and siKDM3A-B-transfected E2-treatedMCF-7 cells. Data are the average of three independent experiments
± SEM. Gene expression is shown relative to that measured in siSCR-transfected cells. (B) MCF-7 cells were transiently transfected with either siSCR,
siKDM3A-B or siKDM3A-C and grown in steroid-depleted media containing 10 nME2 for 54 h in the Incucyte Zoom live cell imager. Cell confluence was
measured every 6 h. Data were normalized for each sample to the cell confluence measured at 0 h. Data are the average of three independent experiments
± SEM. (C) MCF-7 cells were treated as in (B) except grown for 96 h prior to cell counting. Data are the average of three independent experiments ± SEM
and is expressed relative to the number of cells counted in siSCR transfected cells. (D) MCF-7 cells were treated as in (C) prior to analysis using a BrdU
ELISA assay. Data are the average of three independent experiments ± SEM and is expressed relative to the absorbance for BrdU staining measured in
siSCR transfected cells. (E) MCF-7 cells were treated as in (C) prior to harvesting for cell cycle analysis by propidium iodide flow cytometry. Data shows
the % of cells in each phase of the cell cycle and is the average of three independent experiments ± SEM. (F) RNAi rescue experiment in MCF-7 cells (as
described in Figure 3B–E) grown for 156 h prior to cell counting. Data shown is for all siKDM3A transfected cells and is the average of three independent
experiments ± SEM. P-values were determined by Student’s t-test (* denotes P < 0.05).
To assess the phenotypic effect of KDM3A depletion
on cell proliferation, we measured the growth of MCF-7
and T47D cells transfected with siSCR, siKDM3A-B or
siKDM3A-C using live cell imaging, cell counts and a BrdU
ELISA assay. In both BCa cell lines, proliferation was sig-
nificantly reduced in cells depleted of KDM3A; confirm-
ing that KDM3A is required for normal cell growth (Fig-
ure 4B–D; Supplementary Figure S7B–D). Cell cycle anal-
ysis of siSCR, siKDM3A-B and siKDM3A-C-transfected
MCF-7 and T47D cells using propidium iodide flow cytom-
etry also demonstrated that KDM3A depletion caused an
increase of cells in G1 phase of the cell cycle and respec-
tive decrease of cells in S and G2 phases, suggesting that
KDM3A depletion causes G1 cell cycle arrest (Figure 4E;
Supplementary Figure S7E). There was no increase in the
proportion of cells in sub-G1 and no increase in caspase 3/7
activity in either cell line, demonstrating that KDM3A de-
pletion is cytostatic rather than cytotoxic (Supplementary
Figure S7F and G).
We next sought to confirm whether KDM3A catalytic
activity is required for cell growth using RNAi-rescue ex-
periments in MCF-7 cells. Consistent with the ER-target
gene expression rescue experiments (Figure 3), prolifera-
tion was almost doubled in wild-type KDM3A-expressing
cells compared to both KDM3AH1120G/D1122N-expressing
and control KDM3A-depleted cells (Figure 4F), suggesting
that KDM3A catalytic activity is required for MCF-7 cell
growth.
A recent study demonstrated the use of a JmjC domain
targeting compound (JIB-04) to inhibit prostate cancer and
lung cancer growth but showed no detrimental effect on
normal cell types (43). We also observed no impact on cell
growth in the non-transformed breast epithelial cell line
MCF-10A following KDM3A depletion, suggesting that
compounds which affect KDM3A activity may be useful as
tumour specific BCa therapies (Supplementary Figure S8).
KDM3A is required for endocrine therapy-resistant cell
growth
Identifying novel therapeutic targets within the ER sig-
nalling cascade is essential to combat endocrine therapy-
resistant disease. We therefore investigated the effect of
KDM3A depletion on endocrine therapy-resistant BCa
growth. The MCF-7 derived MMU2 cell line is a model
of endocrine therapy-resistant disease that is ER-positive
but can grow in E2-deprived conditions and is resistant
to tamoxifen treatment (45). Although tamoxifen resistant,
MMU2 cells still require ER expression for growth and ER
target gene expression (Supplementary Figure S9A–C). We
transfected MMU2 cells with either siSCR or siKDM3A-
B and demonstrated that KDM3A depletion significantly
down-regulates expression of the ER-target genes pS2,
GREB1, CCND1 and PIM1 (Figure 5A). Western analy-
sis confirmed successful KDM3A depletion inMMU2 cells
(Supplementary Figure S9D). The data therefore indicates
that KDM3A continues to regulate ER signalling in cells
which have developed endocrine therapy resistance. Cru-
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Figure 5. KDM3A is required for ER-target gene expression and cell growth in Tamoxifen-resistant cells. (A) MMU2 cells were transiently transfected
with siSCR and siKDM3A-B and grown for 72 h prior to RNA extraction. Resultant cDNA was analysed for KDM3A, pS2, GREB1, CCND1 and
PIM1 expression by qPCR. Data are the average of three independent experiments ± SEM. Gene expression is shown relative to that measured in siSCR
transfected cells. (B) MMU2 cells were transiently transfected with siSCR, siKDM3A-B and siKDM3A-C and grown for 60 h in the Incucyte Zoom live
cell imager. Cell confluence was measured every 6 hours. Data were normalized to cell confluence measured at 0 h. Data are the average of five independent
experiments ± SEM. P-values were determined by Student’s t-test (* denotes P < 0.05). (C) MMU2 cells were treated as in (B) except grown for 72 h
prior to cell counting. Data are the average of three independent experiments ± SEM and is expressed relative to the number of cells counted in siSCR
transfected cells.
cially, KDM3Adepletion also reducedMMU2 cell prolifer-
ation, suggesting that therapeutics targetingKDM3Acould
potentially be used to treat endocrine therapy-resistant dis-
ease (Figure 5B and C).
DISCUSSION
The suggested role of ER co-regulator proteins in both
BCa development and acquisition of endocrine therapy-
resistance have identified these enzymes as potentially im-
portant BCa therapeutic targets (3). Understanding the
mechanism of regulation as well as the transcriptional and
phenotypic effects of targeting these enzymes is therefore
crucial in developing therapies which target their action.
Using an siRNA screen we identified that the HDM en-
zyme KDM3A was required for expression of the ER tar-
get gene pS2, and using global gene expression analysis
showed that 42% of ER-regulated genes were also regu-
lated by KDM3A. KDM3A has previously been implicated
in regulating ER target-gene expression (18,46), however,
this is the first study to our knowledge which has shown
a significant transcriptome-wide role for KDM3A regula-
tion in ER signalling. KDM3A is up-regulated during hy-
poxia by HIF-1-mediated transcriptional activation and
has been shown to be vital for hypoxia-mediated gene ex-
pression changes (26,27,47). There have been a number
of studies which suggest significant interplay between hy-
poxia and ER signalling pathways and hypoxia has even
been implicated in promoting hormone-independent breast
tumour growth (48–51). Experiments in this study were
not performed under hypoxic conditions and therefore the
impact of KDM3A knockdown was not mediated by hy-
poxia. However, the significant impact on ER signalling
by KDM3A knockdown does suggest that KDM3A activ-
ity may be a link between these two pathways, and could
therefore be a promising target for both ER-positive and
hormone-independent disease.
As well as showing the global impact of KDM3A knock-
down on ER signalling we also identified E2-stimulated
genes down-regulated by KDM3A knockdown that have
important roles in BCa growth and metastasis (PIM1,
LOXL4 and KRT13), suggesting that KDM3A could play
an important role in ER-positive BCa development (37–
42). The identification of such genes could act as biomark-
ers of KDM3A dysregulation and could be used to assess
the success of KDM3A targeting therapies in treating ER-
positive BCa. KDM3A has also been implicated in neurob-
lastoma metastasis (52) and the HDM enzyme KDM4C
has been shown to be a regulator of BCa lung metastasis
and an activator of LOXL2 expression (21). The regulatory
role of these two HDM enzymes on the expression of pro-
metastatic genes therefore suggests that dysregulated his-
tone methylation may play an important role in BCametas-
tasis.
KDM3A removes transcriptionally repressivemono- and
di-methyl marks from H3K9 and has been shown to be
required for successful AR recruitment to AR-target gene
promoters in prostate cancer cell lines upon ligand stim-
ulation (23). Using ChIP, we showed that knockdown of
KDM3A repressed H3K9 demethylation, and abrogated
ER recruitment to cis-regulatory elements within the pro-
moter regions of the ER-target genes pS2 and GREB1 and
at distal enhancer elements of the ER-target genesCCND1,
MYC and XBP1, indicating that KDM3A is also required
for receptor recruitment in ER-positive BCa. Interestingly,
the repressive effect of KDM3A knockdown on H3K9
demethylation and ER recruitment upon E2 stimulation
was less pronounced at the GREB1 promoter compared to
pS2, indicating that multiple HDM enzymes may regulate
some sites and could therefore compensate for KDM3A
down-regulation at specific cis-regulatory elements. For
example, the HDMs KDM1A and KDM4B which reg-
ulate ER transcriptional activity can both demethylate
H3K9me2 and may therefore contribute to redundancy in
epigenetic regulation of specific sites (18,19). Redundancy
in epigenetic regulation of signalling pathways may suggest
that pan-inhibitors of HDM enzymes could be ultimately
more effective as cancer therapeutics than HDM family-,
or enzyme-specific compounds.
We also observed that KDM3A was apparently re-
moved from EREs after hormone stimulation. This was
surprising considering that other ER co-regulators, such
as KDM4B, are recruited to EREs following E2 stimula-
tion (18,19,22,53,54). The cause of E2-stimulated removal
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of KDM3A is currently unclear but may be due to either
epitope masking of the anti-KDM3A antibody by compo-
nents of the active ER complex, or active removal once the
cis-regulatory element is primed to enable recruitment of
additional co-stimulatory proteins.
In order to determine the efficacy of KDM3A as a poten-
tial BCa therapeutic target we sought to identify phenotypic
changes associated withKDM3Aknockdown.GO analysis
of KDM3A regulated genes in ER-positive BCa cells iden-
tified gene clusters associated with cell cycle regulation and
DNA replication. A number of cell cycle regulatory genes
associated with cell cycle progression were down-regulated
by KDM3A knockdown. Consistent with this, knockdown
of KDM3A reduced cell proliferation in both MCF-7 and
T47D cell lines via a cytostatic mechanism. KDM3A de-
pletion has previously been shown to reduce cell growth
in a number of cancer contexts (25–28). Our data support
the observation that KDM3A is important for cancer cell
proliferation and the dramatic cytostatic effect of KDM3A
depletion on BCa cell growth demonstrates that KDM3A
would be an attractive BCa therapeutic target. KDM3A
knockout mouse models are viable with only male germ
cell defects and signs of early onset obesity (55–57). This
fact, coupled with the observation that KDM3A knock-
down had no effect on proliferation of the immortalized,
but non-transformed, breast epithelial cell line MCF-10A,
suggests that therapies targeting KDM3A may have mini-
mal detrimental side-effects, which is an important consid-
eration when validating potential therapeutic targets.
Pan- and selective-inhibitors of HDM enzymes are cur-
rently being developed which work by blocking the catalytic
activity of theirHDM targets (43,44). For example, the pan-
inhibitor JIB-04 is an inhibitor of JmjC domain contain-
ing HDM enzymes which blocks Fe(II) binding. JIB-04 was
shown to affect lung and prostate cancer cell growth with-
out effecting normal, untransformed cell growth indicat-
ing that HDM targeting compounds may be cancer specific
(43). As previously discussed, we have shown a potential
cancer specific growth-inhibitory phenotype uponKDM3A
depletion, indicating targeting KDM3A may be a useful
cancer specific treatment.We have also shown thatKDM3A
catalytic activity is required for both ER signalling and ER-
positive BCa cell growth indicating that compounds which
target KDM3A catalytic activity may be useful as poten-
tial BCa therapies. Although no KDM3 family member-
specific compounds are currently available, selective agents
targeted toHDMs are being developed, supporting the con-
cept that these proteins represent important therapeutic tar-
gets in cancer (44).
Finally, we assessed the effect of KDM3A knockdown
on a model of endocrine therapy-resistant disease. It has
been demonstrated that some endocrine therapy-resistant
BCa models are disengaged from ER signalling (58), how-
ever, some are still reliant on ER expression for growth. The
MMU2 cell line is an establishedmodel of therapy-resistant
ER-positive BCa that was developed by continued long
term culture of MCF-7 cells in 4-hydroxytamoxifen, an ac-
tive tamoxifen metabolite (45). The ER signalling pathway
is functional in these cells in the absence of ligand and in
the presence of Tamoxifen (45) and ER expression is still re-
quired for cell growth.We have shown thatKDM3Aknock-
down down-regulates ER target gene expression in MMU2
cells. This is significant as it demonstrates that KDM3A is
an E2-independent regulator of ER signalling in endocrine
therapy-resistant disease, and therefore may be a useful
treatment to abrogate ER signalling in these cancer types.
Crucially, KDM3A knockdown also inhibited MMU2 cell
growth demonstrating an important phenotypic impact on
endocrine therapy-resistant disease. The effect of KDM3A
knockdown on MMU2 cell growth was not quite as robust
as in MCF-7 and T47D cells suggesting that other HDM
enzymes, for example KDM4B which has been shown to
be a positive regulator of BCa cell growth and is overex-
pressed in BCa, may also play important roles in maintain-
ing therapy-resistant cell growth. The effect of KDM3A
knockdown in therapy-resistant disease therefore suggests
that investigation of other HDM enzymes may provide fur-
ther future therapeutic targets. Endocrine therapy has been
very successful in treating ER-positive BCa, but resistance
to these regimens remains problematic. Identifying targets,
such as KDM3A, that have an effect on the maintenance of
therapy-resistant BCa is therefore crucial in future manage-
ment of the disease.
In summary, we have established that KDM3A is essen-
tial for ER signalling and that KDM3A regulates receptor-
target gene transcription by controlling demethylation of
H3K9me1/me2 at cis-regulatory elements. We have estab-
lished that KDM3A regulates the expression of a number
of genes involved in BCa progression and proliferation and
have convincingly demonstrated that KDM3A is required
for ER positive BCa cell growth. KDM3A was also re-
quired for cell growth in a model for endocrine therapy-
resistant disease. Importantly, we have confirmed that the
catalytic activity of KDM3A is required for both ER sig-
nalling and BCa cell growth and therefore suggest that de-
veloping HDM catalytic-targeting agents would be useful
BCa therapeutics. KDM3A is expressed in BCa tissue and
it has been reported following study of The Cancer Genome
Atlas (TCGA) human breast cancer database (n = 729)
that patients with BCa expressing high levels of KDM3A
had a 3-fold increased risk of death than those with nor-
mal or low KDM3A expressing disease (43). The effect of
KDM3A depletion detailed in this study therefore indicates
that KDM3A is a promising BCa therapeutic target.
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Supplementary Data are available at NAR Online.
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